2024 Multidisciplinary Head and Neck Cancers Symposium onDemand

The 2024 Multidisciplinary Head and Neck Cancers Symposium is a two-and-a-half-day meeting featuring interactive and case-based educational sessions that cover new multidisciplinary therapies, imaging, immunotherapy, treatment guidelines, supportive care and understanding disparities in head and neck cancer. A major focus is placed on the multidisciplinary nature of disease management and the incorporation of all treatment modalities to achieve best outcomes. Oral abstract and poster sessions will highlight cutting-edge science and evidence-based practice. Attendees will be able to examine multidisciplinary approaches for treating head and neck cancer, as well as novel therapies that show promise in improving outcomes.

Target Audience

This meeting is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists, speech language pathologists/scientists, dentists, oral surgeons, swallowing and speech therapists, audiologists, physical therapists, scientists, immunologist and rehabilitation specialists.

Learning Objectives

Upon completion of this activity, participants should be able to do the following:

  • Explain the importance of multidisciplinary care in HNC and how to best apply it for optimal outcomes.
  • Describe key advances in systemic therapy, including targeted therapy and immunotherapy in HNC.
  • Discuss recent advances in minimally invasive surgery in HNC and when to apply it in treating early and locally advanced disease.
  • Illustrate how we can improve disparities in HNC care.
  • Determine the importance of interventions in survivorship clinics for long-term side effects.
  • Describe key advances in radiation therapy delivery, targeting and differences between various modalities, including novel treatment approaches such as proton and FLASH radiotherapy.
  • Discuss complex cases in HNC and how to best utilize current knowledge for decision making.
  • Manage toxicities related to the management of HNC.
  • Summarize key recent advances in HNC biology.
  • Summarize key recent advances in HNC imaging.
  • Discuss and implement standard treatment guidelines for various subtypes of HNCs.
Course summary
Available credit: 
  • 18.25 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 18.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 18.25 Certificate of Attendance
    This activity was designated for 18.25 AMA PRA Category 1 Credit™.
Course opens: 
03/11/2024
Course expires: 
03/10/2026
Cost:
$1,649.00
Rating: 
0

[M] = medical oncologist, [R] = radiation oncologist, [S] = surgeon/surgical oncologist

 

Thursday, February 29


Patient Perspective I

  • Speaker: Mark Laughlin [Patient Speaker]

Novel Local Therapy for Recurrent Disease
Moderator: Maie St. John, MD, PhD, University of California, Los Angeles [S]

  • Novel Drugs and Targets beyond PD1 Inhibitors: Expanding the Treatment Landscape of Recurrent Head and Neck Cancer
    • Robert Haddad, MD, Dana-Farber Cancer Institute, Boston [M]
  • Radiation in the Recurrent Setting: The Evidence, the Science
    • Sana Karam, MD, PhD, University of Colorado Anschutz Medical Campus, Aurora, Colorado [R]
  • The Next 10 Years of I/O in Head and Neck Cancer
    • Young Kim, MD, PhD, Vanderbilt University Medical Center, Nashville, Tennessee [S]
  • Immune Escape and Equilibrium in Head and Neck Cancers
    • Luc Morris, MD, FACS, Memorial Sloan Kettering Cancer Center, New York [S]
  • Q&A

Keynote I: Overcoming Structural Barriers to Diverse Representation and Clinical Trials
Moderator: Kelly Malloy, MD, University of Michigan, Ann Arbor, Michigan [S]

  • Speaker: Carmen Guerra, MD, MSCE, FACP, University of Pennsylvania, Philadelphia [Physician]

Emerging Clinical Decision Support Tools
Moderator: Alexander Pearson, MD, University of Chicago, Chicago [M]

  • AI Tools
    • Ben Kann, MD, Brigham and Women's Hospital, Boston [R]
  • ctDNA
    • Glenn Hanna, MD, Dana-Farber Cancer Institute, Boston [M]
  • Salivary Diagnostics and Liquid Biopsy as Tools for HNC
    • Chamindie Punyadeera, PhD, Griffith University, Queensland, Australia [Professor]
  • Q&A

K. Kian Ang, MD, PhD, FASTRO, Commemorative Plenary Session
Moderator: Robert Ferris, MD, PhD, UPMC Hillman Cancer Center, Pittsburgh [S]

  • Pembrolizumab With or Without Lenvatinib as First-line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSSCC): Phase 3 LEAP-010 Study
    • Lisa Licitra, MD, Fondazione IRCCS Istitutio Nazionale dei Tumori and University of Milan, Milan, Italy [M]
  • Pembrolizumab and Cabozantinib in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma (RMHNSCC): 2-year Long Term Survival Update with Biomarker Analysis
    • Nabil Saba, MD, Emory University, Atlanta [M]
  • Final Analysis of the Phase 4 KEYNOTE-B10 Study: First-Line (1L) Pembrolizumab (pembo) + Carboplatin (carbo) + Paclitaxel (pacli) for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)
    • Marcin Dzienis, MBBS, Gold Coast University Hospital, Southport, Australia [M]
  • A Phase II Trial of Personalized Immunotherapy in Patients (pts) with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M HNSCC) that have Progressed on Prior Immunotherapy
    • Dan Zandberg, MD, UPMC Hillman Cancer Center, Pittsburg [M]
  • HPV Serology and Circulating Viral DNA for Detection, Genotyping, and Risk-Stratification in p16+ Oropharyngeal Cancer
    • Lucas Penny, University of Toronto, Ontario, Canada [PhD Student]
  • Ultrasensitive Liquid Biopsy in Patients with p16-Positive Oropharyngeal Cancer using HPV-Seq
    • Eric Stutheit-Zhao, MD, PhD, Princess Margaret Cancer Center, Toronto, Ontario, Canada [R]
  • Early Disease Recurrence Following Post-Operative HPV ctDNA Directed Active Surveillance in Oropharyngeal Carcinoma – Outcomes of a Prospective Pilot Study
    • Linda Chen, MD, Memorial Sloan Kettering Cancer Center, New York [R]
  • Novel Radioenhancer NBTXR3 Activated by Radiotherapy in Cisplatin-Ineligible Locally Advanced HNSCC Patients: Final and Exploratory Results of a Phase I Trial
    • Christophe Le Tourneau, MD, PhD, Istitut Curie, Paris, France [M]
  • Phase I/II Study of Novel MDM-2 Inhibitor (APG-115-alrizomadlin) in p53 Wild Type Salivary Gland Cancers
    • Paul Swiecicki, MD, University of Michigan, Ann Arbor, Michigan [M]
  • A Phase II Single Arm Trial of Induction and Concurrent Vismodegib with Curative Intent Radiation Therapy for Locally Advanced, Unresectable Basal Cell Carcinoma of the Head and Neck
    • Christopher Barker, MD Memorial Sloan Kettering Cancer Center, New York [R]

Innovative Trials in Systemic Therapy, Radiation and Surgery in Head and Neck Cancers
Moderator: Musaddiq Awan, MD, Medical College of Wisconsin, Milwaukee, Wisconsin [R]
Moderator: Nancy Lee, MD, FASTRO Memorial Sloan Kettering Cancer Center, New York [R]

  • Targeting of HPV-Specific Epitopes in Viral Oropharyngeal Cancer: The Hoopika Study
    • Stuart Wong, MD, Medical College of Wisconsin, Milwaukee, Wisconsin [M]
  • Novel Immunotherapeutic Approaches Prior to Surgical Resection of Non-Viral Head and Neck Cancers
    • Clint Allen, MD, National Institutes of Health, Washington, DC [S]
  • Utilizing a Neoadjuvant Radiotherapy Approach to Develop Novel Immunotherapeutic Targets in Head and Neck Cancers: The HyPR-HN Trial
    • Joseph Zenga, MD, Medical College of Wisconsin, Milwaukee, Wisconsin [S]
  • Dosage Optimization Driving Innovative Clinical Study Design
    • Stacy Shord, PharmD, Deputy Director of Division of Cancer Pharmacology II, Food and Drug Administration, Silver Spring, Maryland
  • Q&A

Friday, March 1


Patient Perspective II

  • Speaker: Dmitry Karpeyev, PhD [Patient Speaker]

Debate on Advanced, Resectable cSCC in the Era of Immunotherapy: Cut Now, Later or Not at All?
Moderator: Jessica Geiger, MD, Cleveland Clinic Cancer Center, Cleveland [M]

  • PT Selection Appropriate for Immunotherapy and Avoiding Surgery
    • Shlomo Koyfman, MD, Cleveland Clinic, Cleveland [R]
  • Advocating for Neo-Adjuvant Immunotherapy Followed by Resection
    • Emily Ruiz, MD, MPH, FAAD, Brigham and Women's Hospital, Boston [S]
  • Argument for Resection Neo-Adjuvant Immunotherapy
    • Steven Chinn, MD, MPH, University of Michigan, Ann Arbor, Michigan [S]
  • Q&A

Keynote II: Evolving Role of Neoadjuvant Immunotherapy in Curative-Intent Head and Neck Cancer
Moderator: Ari Rosenberg, MD, University of Chicago, Chicago [M]

  • Speaker: Ravindra Uppaluri, MD, PhD, Dana-Farber Cancer Center, Boston [S]

Plenary II Session
Moderator: Faye Johnson, MD, PhD, MD Anderson Cancer Center, Houston [M]

  • A Phase 2 Multi-center, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of Parenteral TK-90 for Preventing Radiation-induced Mucositis in Patients with Squamous Cell Carcinoma of the Head and Neck
    • Nabil Saba, MD, Emory University, Atlanta [M]
  • Two-year Intention-to-treat Analysis for Tumor Outcome in Patients Treated with Avasopasem for Oral Cavity and Oral Pharynx Primaries
    • Neal Dunlap, MD, The James Graham Brown Cancer Center at University of Louisville, Louisville, Kentucky [R]
  • Acute Toxicity Results from the Randomized Assessment of Cisplatin Dosing Interval for Ototoxcity (RADIO) Trial Comparing Chemoradiation (CRT) with Cisplatin Q3weekly to Weekly for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LASCCHN)
    • Eric Winquist, MD, London Health Sciences Centre & Western University, London, Ontario, Canada [M]
  • Patient-Reported Outcomes and Financial Toxicity in Head and Neck Cancer (PaRTNer): Longitudinal Assessment of Financial Toxicity and Coping Mechanisms
    • Pooja Karukonda, MD, Duke University Medical Center, Durham, North Carolina [R]
  • Efficacy of a Navigation-Based Intervention vs. Usual Care for Decreasing Delays in Starting Guideline-Adherent Adjuvant Therapy for Patients with Head and Neck Cancer
    • Evan Graboyes, MD, Medical University of South Carolina, Charleston, South Carolina [S]
  • Long-Term Efficacy of Risk-Directed, De-Escalated Post-Operative Adjuvant Therapy for Surgically Resected Locally Advanced, Human Papillomavirus-Positive Oropharynx Squamous-Cell Carcinoma (HPV+OPSCC): A Non-Randomized, Multi-Arm Phase 2 Trial
    • Wade Thorstad, MD, Washington University, St. Louis [R]
  • NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer with Exploratory Biomarker Correlatives
    • Robert Ferris, MD, PhD, UPMC Hillman Cancer Center, Pittsburgh [S]
  • FDG-PET-based Selective De-escalation of Radiotherapy for HPV-Related Oropharynx Cancer: Results from a Phase II Trial
    • Samuel Regan, MD, University of Michigan, Ann Arbor, Michigan [R]
  • Early Outcomes for a Single-arm Phase I/II Trial of Selective Avoidance of Nodal VolumEs at Minimal Risk (SAVER) in the Contralateral N0 Neck of Patients with p16-positive Oropharynx Cancer
    • Jason Molitoris, MD, PhD, University of Maryland, Baltimore [R]
  • Criteria for the Diagnosis of Extranodal Extension Detected on Radiological Imaging in Head and Neck Cancer: HNCIG International Consensus Recommendations
    • Christina Henson, MD, University of Oklahoma, Oklahoma City [R]

Thyroid Cancer Roundtable 2024 – From Microcarcinoma to Advanced Management
Moderator: Brian Burkey, MD, MEd, FACS, Cleveland Clinic, Cleveland [S]

  • Management of Microcarcinoma Including RFA
    • ​Caitlin McMullen, MD, Moffitt Cancer Center, Tampa, Florida [S]
  • Neoadjuvant Targeted Therapy and Surgery for Advanced Thyroid Cancers
    • Mark Zafereo, MD, FACS, MD Anderson Cancer Center, Houston [S]
  • Recurrent Laryngeal Nerve Invasion and Management of Thyroid Cancers
    • ​Greg Randolph, MD, FACS, FACE, Mass General Brigham/Mass Eye and Ear, Boston [S]
  • Targeted Therapy for RET Mutations in 2024
    • ​Jennifer Choe, MD, Vanderbilt University, Nashville, Tennessee [M]
  • Q&A

HPV Negative HNSCC: Understanding Biology and the Path to Progress
Moderator: Dan Zandberg, MD, UPMC Hillman Cancer Center, Pittsburgh [M]

  • Genomic Alterations and Important Molecular Pathways in HPV Negative Patients
    • Christine Chung, MD, Moffitt Cancer Center, Tampa, Florida [M]
  • The Tumor Immune Microenvironment in HPV Negative Patients
    • Andrew Sikora, MD, PhD, MD Anderson Cancer Center, Houston [S]
  • Current Status and Future Directions in the Curative Intent Therapy in HPV
    • Doug Adkins, MD, FACP, Washington University, St. Louis [M]
  • Current Status and Future Directions in the Recurrent/Metastatic Setting in HPV Negative Patients
    • Nabil Saba, MD, FACP, Emory University, Atlanta [M]
  • Q&A

Multidisciplinary Management of Advanced or Recurrent Salivary Cancer
Moderator: Michael Moore, MD, Indiana University, Indianapolis [S]

  • Extent of Surgery for Primary Malignant Parotid Tumors
    • Samer Al-Khudari, MD, Rush University, Chicago [S]
  • From Zero to Proton Therapy: Indications for Adjuvant Radiotherapy in Salivary Cancer
    • ​Annie Chan, MD, Massachusetts General Hospital, Boston [R]
  • Molecular Profiling of Salivary Cancer: Indications and Applications
    • ​Renata Ferrarotto, MD, MD Anderson Cancer Center, Houston [M]
  • Q&A

Saturday, March 2


Patient Perspective III

  • Speaker: Molly Cassidy, JD [Patient Speaker]

New Advances and Contemporary Management of Viral-Driven Head and Neck Cancer
Moderator: C. Jillian Tsai, MD, PhD, MS, Princess Margaret Cancer Center, Toronto, Ontario, Canada [R]

  • Advances in NPC Systemic and Other Novel Therapeutics
    • Lauren Shih​, MD, University of Washington, Seattle [Resident Physician]
  • Molecular Profiling of Treatment Responses and Personalized Therapy for NPC
    • ​Melvin Lee Kiang Chua, MBBS, PhD, National Cancer Centre, Singapore [R]
  • Early Detection and Disease Surveillance for HPV-Related Oropharyngeal Cancers
    • Eleni Rettig, MD, Brigham and Women's Hospital, Boston [S]
  • Trends and Controversies in HPV De-Escalation Trials
    • ​Daniel Ma, MD, Mayo Clinic, Rochester, Minnesota [R]
  • Q&A

Supportive Care Interventions: A Focus on Treatment-Related Complications of the Oral Cavity and Oropharynx
Moderator: Assuntina Sacco, MD, University of California San Diego, La Jolla, California [M]

  • Advances in Oral Mucositis Management from Head and Neck Chemoradiation: Successes, Failures and Future Directions
    • ​Carryn Anderson, MD, University of Iowa Health Care, Iowa City, Iowa [R]
  • An Innovative Approach to Managing Oral Complications in Head and Neck Cancer Patients
    • Deborah Saunders, DMD, Health Sciences North Research Institute, Sudbury, Ontario, Canada [Dentist]
  • Dysphagia as a Complication of Immunotherapy: Recognizing the Nuances through Early Identification, Monitoring and Intervention
    • ​Kristen Linnemeyer, SLP, University of California, San Diego [Speech-Language Pathologist]
  • Q&A

Beyond the Battle: A Multidisciplinary Perspective on Head and Neck Cancer Survivorship
Moderator: Farzan Siddiqui, MD, PhD, Henry Ford Hospital, Detroit [R]

  • Body Image: A Critical Care and Under-Appreciated Concern among Head and Neck Cancer Survivors
    • ​Evan Graboyes, MD, Medical University of South Carolina, Charleston, South Carolina [S]
  • Going beyond Function: Developing a Life Worth Living in HNC Survivorship
    • ​Amy Williams, PhD, Corewell Health, Southfield, Michigan [Clinical Psychologist]
  • A Multidisciplinary Head and Neck Survivorship Program in a Comprehensive Cancer Center
    • ​Melanie Woodside, RN, CON(C), University Health Network, Toronto, Ontario, Canada [Clinical Nurse Specialist]
  • Financial Toxicity in Long Term Survivors of Head and Neck Cancer
    • ​Zachary Zumsteg, MD, Cedars-Sinai Medical Center, Los Angeles [R]
  • Q&A

Faculty:
A list of all faculty and their individual disclosures can be found on the Schedule of Events page.

Planning Committee:
A list of all meeting planning committee members and their individual disclosures can be found on the Planning Committee web page.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.

Available Credit

  • 18.25 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 18.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 18.25 Certificate of Attendance
    This activity was designated for 18.25 AMA PRA Category 1 Credit™.
 
Status
Price
Title
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.

Price

Cost:
$1,649.00
Please login or register to take this course.

Course Fees: ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.

  •  Nonmember: $1649
  •  Member: $1199
  • Member-in-Training: $899
  • Student: $449
     

Policies:
No refunds, extensions, or substitutions will be made for those registrants. Including those who for any reason,  have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.

Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.

The course and its materials will only be available on the ASTRO website for that 2 year period regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.”

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.